Presentation

WHO and EMA statements on Potential safety issue affecting women living with HIV using dolutegravir

Tags: | June 1st, 2018

Important information has been issued by the World Health Organization and the European Medicine Agency in order to highlight potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

Read the full World Health Organization statement and the European Medicines Agency press release dated 18/05/2018, relaunched on the AIFA website.